>
pdufa.bio

Remibrutinib

Updated ยทnext FDA decision on the calendar

Remibrutinib is a Novartis Ag program. Its next catalyst is a Readout in Jun 2027. Every date links its source.

NVS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Novartis Ag (NVS). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Jun 2027NVS

Questions

When is Remibrutinib's next FDA decision or readout?

The next tracked catalyst for Remibrutinib is a Readout in Jun 2027.

What happened at Remibrutinib's most recent FDA decision?

No FDA decision for Remibrutinib is in our archive yet.

Who makes Remibrutinib?

Novartis Ag (NVS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.